Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexarotene remyelination study in relapsing-remitting multiple sclerosis
2014-003145-99Phase 2Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Jan 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in multiple sclerosis (MS) comparing Bexarotene plus interferon-beta with Placebo plus interferon-beta (2 arms). Primary endpoint: Adverse events and withdrawals attributable to bexarotene. Started Jan 2015; status: completed.
02
Drugs
bexarotene
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2014-003145-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003145-99.